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Abstract—Objective: To examine whether the presence of motor signs has predictive value for important outcomes in
Alzheimer disease (AD). Methods: A total of 533 patients with AD at early stages (mean Folstein Mini-Mental State
Examination [MMSE] 21/30 at entry) were recruited and followed semiannually for up to 13.1 years (mean 3) in five
University-based AD centers in the United States and European Union. Four outcomes, assessed every 6 months, were
used in Cox models: cognitive endpoint (Columbia Mini-Mental State Examination  20/57 [MMSE  10/30]), functional
endpoint (Blessed Dementia Rating Scale  10), institutionalization equivalent index, and death. Using a standardized
portion of the Unified PD Rating Scale (administered every 6 months for a total of 3,149 visit-assessments, average 5.9 per
patient), the presence of motor signs, as well as of individual motor sign domains, was examined as time-dependent
predictor. The models controlled for cohort, recruitment center, sex, age, education, a comorbidity index, and baseline
cognitive and functional performance. Results: A total of 39% of the patients reached the cognitive, 41% the functional,
54% the institutionalization, and 47% the mortality endpoint. Motor signs were noted for 14% of patients at baseline and
for 45% at any evaluation. Their presence was associated with increased risk for cognitive decline (RR, 1.72; 95% CI, 1.24
to 2.38), functional decline (1.80 [1.33 to 2.45]), institutionalization (1.68 [1.26 to 2.25]), and death (1.38 [1.05 to 1.82]).
Tremor was associated with increased risk for reaching the cognitive and bradykinesia for reaching the functional
endpoints. Postural-gait abnormalities carried increased risk for institutionalization and mortality. Faster rates of motor
sign accumulation were associated with increased risk for all outcomes. Conclusions: Motor signs predict cognitive and
functional decline, institutionalization, and mortality in Alzheimer disease. Different motor sign domains predict different
outcomes.
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Motor signs are commonly observed in Alzheimer
disease (AD).1-4 Because their exact mechanism and
anatomic location of origin is not clear, in this article
we use the term motor signs to refer to what is
usually described in the literature as extrapyramidal
signs or parkinsonian signs or parkinsonism.
As compared to patients with AD without motor
signs, patients with AD with motor signs have
higher annual total cost of care.5 In addition, infor-
mation about presence of motor signs in AD is impor-
tant because they may predict cognitive6-9 and
functional2,10 decline, institutionalization,2,10 and
death.10-16 However, some reports failed to detect sig-
nificant associations for cognition,2,17-19 function,17,18,20
institutionalization,20 or mortality.21,22
Many factors contribute to the variability in re-
ported associations between motor signs and AD out-
comes. Some of the inconsistency derives from
variability in the definitions of motor signs, inconsis-
tent consideration of treatments with neuroleptics,
use of standardized scales vs clinical evaluation,
small sample size resulting in limited power, inclu-
sion of subjects at varying stages of disease, and
variable levels of participation at and duration of
follow-up. Also, many studies considered motor signs
globally, and only a few reports have focused on indi-
vidual domains of motor signs. In addition, most pre-
vious studies considered motor signs only at a single
point during the course of AD, typically at the base-
line visit or less frequently at any point during the
disease course. Because of the progressive nature of
AD, motor signs are not static and invariable but
may fluctuate from visit to visit.3,4 Therefore, consid-
eration of motor signs as fixed predictors may lead to
biased results.
To obtain a more definitive answer to these ques-
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tions, we analyzed data from the Predictors Study, a
large, multicenter study of patients with probable
AD followed from the early stages of the disease for
up to 13 years. Standardized assessments of motor
signs were administered semiannually. We assessed
their association with four outcomes: cognitive end-
point, functional endpoint, institutionalization, and
death. Taking advantage of the multiple assess-
ments of motor signs throughout the course of the
disease, we were able to consider their predictive
ability in a time-dependent fashion.
Methods. Participants. Subjects from two Predictors Study co-
horts23 were included in these analyses. For the Predictors 1 co-
hort, patients were recruited and studied at three sites in the
United States: Columbia University, New York; Johns Hopkins
University, Baltimore; and Harvard University, Boston. For the
Predictors 2 cohort, two additional sites in the European Union
were added: Hospital de la Salpetriere, Paris, France; and Univer-
sity of Thessaly, Larissa, Greece. The study was approved by the
appropriate local Institutional Review Boards.
The inclusion and exclusion criteria, as well as the evaluation
procedures of the Predictors Study, have been described in more
detail elsewhere.23,24 Briefly, patients met Diagnostic and Statisti-
cal Manual of Mental Disorders (DSM-III-R) criteria for primary
degenerative dementia of the Alzheimer type and National Insti-
tute of Neurologic Disorders and Stroke-AD and Related Disor-
ders Association criteria for probable AD. Enrollment required a
Columbia Mini-Mental State Examination (CMMS) score of 30 or
more (maximum CMMS score, 57), which is equivalent to a score
of approximately 16 or more on the Folstein Mini-Mental State
Examination (MMSE).25,26 There were 42 patients who were re-
cruited despite having CMMS score of  30 at baseline. Because
their exclusion did not change the results, we included them in
the present analyses. Exclusion criteria were diagnosis of PD or
parkinsonism at any time prior to the onset of dementia, history of
alcohol abuse or dependence, any electroconvulsive treatment
within 2 years of recruitment or 10 or more electroconvulsive
sessions at any time, history or current clinical evidence of schizo-
phrenia or schizoaffective disorder that started before the onset of
intellectual decline, and evidence of stroke from either medical
history or clinical examination or a Hachinski Ischemic Score of 
5 or strokes in cortical areas or focal atrophy resulting from focal
infarcts in either CT or MRI. Periventricular or subcortical abnor-
mal CT or MRI signals consistent with small vessel ischemic
changes and small lacunes were permitted. Each consecutive pa-
tient who met these study criteria was included, except for those
who did not consent to participate or who lived too far away and
were unable to return to the hospital for regular follow-up.
During follow-up, in every bi-annual assessment the occur-
rence of a stoke during the last 6 months was recorded. Overall 15
patients developed a stroke at some point during the follow-up.
Because excluding them did not change the results they are con-
sidered in the presented analyses. Patients’ clinical diagnoses
were revisited yearly and only subjects who were consistently
thought to have clinical AD were included in the analyses. Over-
all, 109 patients have come to autopsy examination. The postmor-
tem diagnostic procedure has been completed for 96 patients, 96%
of whom had AD-type pathologic changes (90% received the patho-
logic diagnosis of AD and 6% had senile changes of the Alzheimer
type). Dementia with Lewy bodies was diagnosed in 23% (coexist-
ing with AD-type changes in all but 1 patient). In the analyses
presented in this article all subjects with clinical diagnosis of AD
(irrespective of pathologic confirmation) were included. In second-
ary analyses, which excluded the few autopsied cases that did not
have AD-type pathologic changes, the results were unchanged.
Evaluation. Predictors. At the initial visit, demographic
characteristics (age, ethnicity, sex, education) were recorded and
disease severity features were assessed.
Motor signs were assessed by trained examiners using a modi-
fied Unified Parkinson’s Disease Rating Scale (UPDRS) that has
good inter-rater reliability properties in dementia populations.27
More specifically, excellent agreement for all five rigidity items
and gait and fair to good agreement for speech, facial expression,
posture, and body bradykinesia-hypokinesia has been demon-
strated for the use of this scale.27 Because no tremor was detected
in our earlier study, adequate assessment of tremor reliability
could not be performed, but good to excellent reliabilities for the
UPDRS tremor items have been demonstrated in other studies.28
The following 11 items were rated on a scale of 0 to 4 (with 0
being normal and 4 indicating maximum impairment): speech,
tremor at rest (in any limb), facial expression, neck rigidity, right
arm rigidity, left arm rigidity, right leg rigidity, left leg rigidity,
posture, gait, body bradykinesia-hypokinesia. For clinical pur-
poses, the 11 items were grouped into the following five domains:
Speech-Facial Expression (2 items, range 0 to 8), Tremor (1 item,
range 0 to 4), Rigidity (5 items, range 0 to 20), Posture-Gait (2
items, range 0 to 8), and Bradykinesia (1 item, range 0 to 4). The
grouping of individual UPDRS items into the five domains was
guided by the following: 1) previous classifications that our
group4,27,29 has used, 2) classifications used by other groups,2,3 3)
factor analyses performed in multiple other cohorts,30 and 4) a
principal component analysis with varimax rotation—Kaiser nor-
malization using data from the first evaluation of our patients,
which produced factors broadly corresponding the above domains.
A dichotomous motor sign variable was used: total score of  2 vs
total score of  2. The reason for this cutoff is as follows: 1) we
previously demonstrated good interrater reliability for severity at
least mild to moderate (i.e., score greater than 1 [which indicates
slight severity]),27 and 2) this level of severity is also more likely to
be noted by the average clinician. The domain subscores were also
used in dichotomous forms (domain score of  2 [if any of the
items constituting the domain had a score  2] vs domain score of
 2). Total motor signs score (sum of all items) was included in
the analyses in the form of continuous variable (range 0 to 44).
The domain subscores were also utilized in a continuous form
(sum of individual items of each domain). When interpreting the
results we considered as most important only the associations
noted with both the dichotomous and the continuous forms of
motor sign domains.
Only non-drug induced motor signs were considered for these
analyses. More specifically, at every 6-month visit the following
two items were recorded: 1) Was the patient on medications that
could cause motor signs (such as neuroleptics)? 2) Had the patient
taken such medications in the past but did not continue to do so?
If there was an affirmative answer to either of the two questions,
the particular subject-evaluation was excluded from the analyses.
In supplementary analyses we completely excluded all evaluations
of subjects who ever had drug-induced motor signs and recom-
puted the models in the remaining 371 patients: the results were
essentially unchanged.
A modified version of the Charlson Index of Comorbidity31 (re-
ferred to as comorbidity index) included items for myocardial in-
farct, congestive heart failure, peripheral vascular disease,
hypertension, chronic obstructive pulmonary disease, arthritis,
gastrointestinal disease, mild liver disease, diabetes, chronic renal
disease, and systemic malignancy from initial visit. All items re-
ceived weights of one, with the exception of chronic renal disease
and systemic malignancy, which were weighted two. No patients
with clinical strokes, metastatic tumors, or AIDS were included in
the sample. At baseline visit 67% of patients had a comorbidity
index of 0, 19% an index of 1, 9% an index of 2, 4% an index of 3,
and 1% an index of 4. Therefore, dichotomized scores (0 [67%] vs
1 [33%]) were used. Exploratory use of the index in a trichoto-
mized (0 vs 1 vs 2) or a continuous form did not change the
results.
Outcomes. Cognitive outcome. Neurologic and mental status
examinations were conducted at study entry and at 6-month inter-
vals thereafter. The cognitive function measure used for the anal-
ysis was the CMMS25,26 (in English for the US sites and in French
and Greek translated versions for the EU sites). This is a 57-point
version of the original MMSE25 that includes the addition of digit
span forward and backward, two additional calculation items, re-
call of the current and four previous political leaders of the coun-
try, confrontation naming of 10 items from the Boston Naming
Test, one additional sentence to repeat, and a different copy task
including two figures. We used a CMMS score of  20/57 (equiva-
lent to MMSE  10/30) as the cognitive outcome endpoint. This
cutoff was chosen because 1) it marks the transition from the
moderate to severe stage of the disease and therefore represents a
clinically significant landmark and 2) similar outcome scores have
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been previously used.2,32 Exploratory analyses of neighboring end-
points (i.e., CMMS  15) did not change the results.
Functional outcome. Functional capacity was assessed using
the Blessed Dementia Rating Scale (BDRS) parts I and II.33 The
range is between 0 and 17, with higher scores indicating worse
functional status. We chose a BDRS score of  10/17 as the func-
tional endpoint. The rationale for the functional cutoff was similar
to the one described above for the cognitive cutoff. Again, explor-
atory analyses of neighboring BDRS endpoints gave similar
results.
Institutionalization. The “equivalent institutional care”34 that
the patient was receiving was rated at each 6-month follow-up
interval. This rating is the second section of a Dependency Scale34
that rates the patient’s need for care. It summarizes the inter-
viewer’s impression, based on data from the entire study protocol,
of the care the patient receives and requires, regardless of the
patient’s location. Rating categories are limited home care (inde-
pendent living, with some help in shopping, cooking, or house-
keeping but not with all the tasks); adult home (a supervised
setting with regular assistance in shopping, cooking, and house-
keeping and constant companionship, security, legal, or financial
help); and health-related facility (around-the-clock supervision of
personal care, safety, or medical care). We used the equivalent insti-
tutional care rating of health related facility as an endpoint for pre-
diction. Interrater reliability for the equivalent institutional care is
good, with an intraclass correlation coefficient of 0.73.34
Death. We typically learned of patients’ deaths via family
member contacts or during attempted follow-up. For patients who
could not be contacted for Predictors Study follow-up or were
otherwise lost to follow-up, death information was obtained as
available through the National Death Index. Autopsies were ob-
tained whenever possible.
Statistical analyses. Baseline characteristics of patients who
did and those who did not reach the four outcomes of interest
during the study period were compared using Student’s t test for
continuous variables and 2 test for categorical variables.
We calculated separate Cox proportional hazards models with
the following dichotomous outcomes: cognitive endpoint, func-
tional endpoint, institutionalization, and death. Duration (in
6-month blocks) between the initial visit and either development
of the outcome or last evaluation without the outcome served as
the timing variable in each above model. In initial models, we
considered presence of motor signs at baseline evaluation as a
potential predictor. The main analyses considered motor signs, in
the form of a time-dependent covariate. In additional Cox models,
all five individual motor signs domains (time-dependent) were
included in the analyses in a stepwise forward selection mode
(entry criterion: p  0.05; removal criterion: p  0.05). The Cox
proportional hazards model with time-dependent covariates takes
into account changes in the status of the predictor variable at each
study visit (e.g., a patient may not have motor signs at the first
visit but may manifest motor signs at the second and third visit).
In subsequent Cox models, we simultaneously adjusted for the
following variables: cohort (first or second Predictors cohort; di-
chotomous), recruitment center (dummy variable with New York
center as the reference), age at intake in the study, sex, education
in years, CMMS score at initial evaluation, BDRS score at initial
evaluation, and the comorbidity index (dichotomous). Because the
ethnic distribution of the patients enrolled in the Predictors study
was heavily weighted toward whites (93%) with very few African
Americans (4.8%) or Hispanics (2.7%), no ethnicity variable was
included in the models.
In supplementary analyses we examined the effect of rates of
accumulation of motor signs in reaching the outcomes. For pa-
tients who had at least three motor sign assessments we calcu-
lated slopes of total motor signs continuous-sum scores. We then
selected patients with total motor sign score slopes  0 (n  244),
dichotomized by median slope, and created two groups: one that
exhibited faster and one that exhibited slower accumulation of
motor signs over time. We then calculated Cox models for all four
outcomes including the above dichotomous variable (fast vs slow
motor sign accumulation) as the main predictor, controlling for
baseline total motor signs score, cohort, recruitment center, age,
sex, education, CMMS score at initial evaluation, BDRS score at
initial evaluation, and the comorbidity index.
Results. Overall, 533 subjects with AD, approximately
half from Predictors 1 and half from Predictors 2 cohort,
were included in the study (table 1). The majority of pa-
tients (86%) were recruited from the three centers in the
United States. As dictated by the inclusion criteria, pa-
tients were at the early stages of AD at the time of initial
recruitment: CMMS was 38.2, corresponding to a MMSE of
21. The subjects were, on average, well educated (aver-
age 13.1 years of education) and in good general health (as
indicated by the fact that 2/3 had a comorbidity index of 0).
Patients were followed for up to 13.1 years, during
which time there were 3,149 visit-assessments of motor
signs (up to 26, on average 5.9 per patient). The relatively
short average duration of follow-up (3 years) reflects 1)
the continuous accrual of subjects even at present and 2)
that approximately half of the recruited patients have died
(median survival from recruitment into the study was 6.3
years [5.7 to 6.9]). During the period each subject was
followed, missed visits were rare: 18% missed more than
one semi-annual visit and 9% missed more than two.
Table 1 Demographic and clinical characteristics of patients
Characteristics Value
Cohort 1/Cohort 2, n (%) 252 (47)/281 (53)
Recruitment center, n (%)





Duration of follow-up, y, mean (SD) 3.05 (2.94)
Age at study entry, y, mean (SD) 73.9 (8.81)
Education, y, mean (SD) 13.1 (4.05)
Men/women, n (%) 208 (39)/323 (61)
CMMS at study entry, mean (SD) 38.2 (7.41)
BDRS at study entry, mean (SD) 3.7 (2.21)
Comorbidity Index 0/Comorbidity
Index  1, n (%)
358 (67)/175 (33)
Main predictors (motor signs), n (%)






Tremor baseline/any evaluation 21 (4)/56 (11)
Rigidity baseline/any evaluation 30 (6)/131 (26)





Cognitive endpoint during follow-up 199 (39)
Functional endpoint during follow-up 208 (41)
Institutionalized during follow-up 253 (54)
Dead during follow-up 242 (47)
CMMS  Columbia Mini-Mental State Examination; BDRS 
Blessed Dementia Rating Scale.
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Follow-up was complete for 94.5% of the cohort, while only
5.5% of the cohort (n  27 subjects) had missing follow-up
information for the period of the last year before the most
updated data entry. Rates of missing individual motor sign
items (when the modified UPDRS scale was administered)
ranged between 0.7% and 4.5%.
At the baseline evaluation, motor signs were present for
14%, while 45% of the patients developed motor signs at
some point during follow-up. Frequencies of individual mo-
tor sign domains at baseline were 4 to 6%. As expected,
tremor was less frequent: 25% of the patients had either
speech-facial expression or rigidity or posture-gait or bra-
dykinesia abnormalities, while only 11% had tremor at
some point during follow-up. Details of changes of motor
signs during the disease course have been published.4
Briefly, total motor signs score increased at an annual rate
of 3% of total possible score. Prevalence of motor signs
increased as disease chronicity increased: first year 18%,
second year 19%, third year 25%, fourth year 33%, fifth
year 46%, sixth year 41%, seventh year 39%, eighth year
47%, ninth year 90%, 10th year 67%, 11th year 62%, 12th
year 64%, 13th year 71%.
Adjusting for cohort, recruitment center, age, sex, edu-
cation, baseline CMMS, baseline BDRS, and comorbidity
index, presence of motor signs in a dichotomous form at
initial evaluation was predictive of poor functional out-
come (RR: 1.87 [1.24 to 2.82]) and death (RR: 1.66 [1.15 to
2.38]) but not of poor cognitive outcome (RR: 1.37 [0.91 to
2.07]) or institutionalization (RR: 1.41 [0.98 to 2.03]). Sim-
ilarly, motor sign continuous-sum score at baseline was
predictive of poor functional outcome (RR: 1.05 [1.02 to
1.09]) and death (RR: 1.06 [1.03 to 1.09]) but not of poor
cognitive outcome (RR: 1.03 [0.99 to 1.07]) or institutional-
ization (RR: 1.01 [0.98 to 1.04]).
In survival analyses, presence of time-dependent motor
signs was associated with increased risk of reaching all
four outcomes in both adjusted and unadjusted models, in
either dichotomous or continuous-sum form (tables 2 and
3). Overall, 39% of the patients reached the cognitive end-
point. The associations between motor signs and cognitive
outcome were driven primarily by tremor (see tables 2 and
3). The functional endpoint was reached by 41% of the
patients and it was mostly the presence of bradykinesia
that predicted poor functional outcome (see tables 2 and 3).
Slightly more than half of the patients (54%) reached the
equivalent institutional care endpoint and slightly less
than half (47%) died during the follow-up period. It was
patients with posture-gait impairment that were mostly at
risk for institutionalization and death (see tables 2 and 3).
With regard to the effects of the other covariates, the
results were as follows (table E-1 on the Neurology Web
site at www.neurology.org). As compared to the New York
center, risk for institutionalization was higher for the Bos-
ton center. Women had higher risk for institutionalization
and lower risk for mortality than men. Older patients were
less likely to reach the cognitive endpoint but more likely to
die. Higher baseline CMMS was associated with reduced risk
of reaching all the outcomes. Higher baseline BDRS (indicat-
ing worse functional status) was associated with higher risk
for functional outcome and institutionalization. Presence of
comorbid conditions was associated with higher risk of reach-
ing the institutionalization and death endpoints.
Adjusting for baseline motor sign sum score, cohort,
recruitment center, age, sex, education, baseline CMMS,
baseline BDRS, and comorbidity index, patients who accu-
mulated motor signs faster had higher risk of reaching the
cognitive (RR: 1.58 [1.09 to 2.27]), functional (RR: 1.81
[1.26 to 2.61]), institutionalization (RR: 1.43 [1.03 to 2.00]),
and death (RR: 1.69 [1.19 to 2.40]) outcomes.
Discussion. In this study, presence of motor signs
during the course of AD was associated with higher
risk for cognitive and functional decline, institution-
alization, and death. All these associations were sig-
nificant even after adjusting for multiple potential
confounders. Regarding individual aspects of motor
signs, presence of tremor was associated with in-
creased risk for cognitive decline, presence of brady-
kinesia with increased risk for functional decline,
and presence of postural-gait impairments with in-
creased risk for institutionalization and death.












Any motor signs 1.98 (1.46–2.69) 2.55 (1.90–3.41) 2.14 (1.62–2.84) 1.55 (1.20–2.02)
Adjusted models




Bradykinesia 1.97 (1.30–2.98) 2.42 (1.68–3.50)
Posture-gait 1.70 (1.16–2.49) 1.56 (1.17–2.06)
The models of the 1st and 2nd row included any motor signs (in dichotomous form) as time-dependent predictor. In the model shown in
the remaining rows all individual domain motor signs (dichotomous, time-dependent) were included in a stepwise forward selection
mode (only significant results are tabulated). Adjusted models simultaneously controlled for cohort, recruitment center, age, sex, educa-
tion, baseline CMMS, baseline BDRS, and comorbidity index.
CMMS  Columbia Mini-Mental State Examination; BDRS  Blessed Dementia Rating Scale.
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Faster rate of motor sign accumulation was also as-
sociated with higher risk for reaching all outcomes.
Associations of motor signs with functional decline
and institutionalization have been noted in previous
studies, including those that used the Predictors 1
cohort.35 However, the present analyses are much
more powerful since we included more than twice as
many patients with AD, and data from an additional
6 to 8 years of follow-up. Data from two EU centers
were also included, improving the generalizability of
the findings. Additionally, we separately examined
individual motor sign domains, rates of motor sign
accumulation, and controlled for additional covari-
ates, including comorbid diseases.
The noted frequencies of motor signs were within
previously reported ranges.1-4 Of importance is the
notable discrepancy between the frequency of motor
signs in the first and all subsequent evaluations.
Only 1/3 of patients who had motor signs at some
point during the follow-up had them at first visit.
These results reflect the increasing prevalence of
these symptoms during the course of disease.3,4
Therefore, the usual approach of considering the
presence of these symptoms only at baseline could be
one of the major explanations for discrepant predic-
tive ability results in the literature. Our own results
actually contest this, since motor signs at baseline
were significantly associated with some, but not with
some other outcomes, while there was a significant
relation with all outcomes when the time-dependent
version of motor signs was used.
Use of neuroleptic medications in AD may affect
the natural course of the disease, since it has been
associated with poor outcomes.36 The noted association
between motor signs and poor outcomes in this study
was not confounded by medication effects. It is possible
that motor abnormalities in patients taking neurolep-
tics are not completely caused by medications but are
also partially accounted by AD-related enhanced sensi-
tivity to neuroleptics. However, because it is not possi-
ble to separate the relative contribution of these two
factors and in order to increase our confidence that the
occurrence of motor signs in the present study is
strictly related to the underlying disease process, we
analyze only non-drug induced motor signs.
We used motor signs in both dichotomous and con-
tinuous forms. Each approach has its own merits.
Use of the continuous form makes better use of the
full range of the recorded data and is more powerful.
On the other side, using the dichotomous form pro-
vides a more practical tool for everyday clinical prac-
tice. Close inspection of tables 2 and 3 reveals that
use of different forms produces very similar results.
For example, in the adjusted models the results were
identical for institutionalization and death (posture-
gait being the only significant predictor in both its
dichotomous and continuous form). Similarly, the
cognitive outcome was predicted by tremor (in both
its dichotomous and continuous form) and the func-
tional outcome by bradykinesia (in both its dichoto-
mous and continuous form). Discrepancies have to do
mostly with the metric properties of the measures. We
concentrate more in associations deemed significant for
both the dichotomous and continuous version of motor
signs, in both adjusted and unadjusted models.
In previous studies, tremor has been associated
with higher risk for functional decline2 and mortali-
ty.12 In this study we noted associations between
tremor and functional decline and tremor and mor-
tality, but the relationships did not reach signifi-
cance in the adjusted models. Tremor in the present
study was mostly associated with higher risk for cog-
nitive decline. In accordance to one study10 (but not
another2), we found an association between bradyki-
nesia and poor functional outcomes. As in our study,
previous research has found gait disorder to be asso-
ciated with increased mortality in patients with PD37
and even in nondemented elderly.38 Postural and gait











Total motor signs sum 1.07 (1.04–1.10) 1.11 (1.08–1.13) 1.08 (1.05–1.11) 1.02 (1.01–1.04)
Adjusted models
Total motor signs sum 1.05 (1.02–1.08) 1.08 (1.05–1.11) 1.05 (1.02–1.07) 1.02 (1.00–1.04)
Speech-facial expression sum 1.24 (1.08–1.42) 1.16 (1.01–1.33)
Tremor sum 1.49 (1.17–1.90)
Rigidity sum 1.06 (1.00–1.13)
Bradykinesia sum 1.24 (1.01–1.53)
Posture-gait sum 1.19 (1.07–1.32) 1.12 (1.04–1.20)
The models of the 1st and 2nd row included total motor signs sum score as time-dependent predictor. In the model shown in the re-
maining rows all individual domain motor signs sum scores (time-dependent) were included in a stepwise forward selection mode (only
significant results are tabulated). Adjusted models simultaneously controlled for cohort, recruitment center, age, sex, education, base-
line CMMS, baseline BDRS, and comorbidity index.
CMMS  Columbia Mini-Mental State Examination; BDRS  Blessed Dementia Rating Scale.
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abnormalities may have placed patients at higher
risk for institutionalization and death via increased
risk of falling.
Motor signs may reflect higher burden or different
type or more biologically detrimental localization of
neuropathology. It is conceivable that the association
of different aspects of motor signs with different out-
comes may be reflecting varying underlying neuro-
transmitter systems being affected. For example, in
PD, tremor and bradykinesia have been viewed as
representing more purely dopaminergic manifesta-
tions, while posture, balance, and gait disorders may
be mediated by other neurotransmitter systems in
addition to dopamine.39,40 The underlying pathologic
substrate of motor signs in AD is not clear. They
may41,42 or may not43-47 be associated with Lewy bod-
ies. As previously published,4 in this study motor
signs were not significantly related to Lewy bodies.
Extranigral lesions involving mesocortical dopami-
nergic pathways,9 loss of striatal dopamine trans-
porter sites,48 and reduced dopaminergic D2
receptors in the putamen49 have also been invoked.
The dopaminergic system may not be involved in the
manifestation of motor signs in AD10,50 or may be
involved but via AD pathology itself.51
Our findings with regard to the covariates used in
the adjusted models are consistent with previously
reported results. Younger age has been associated
with more rapid cognitive decline and worse out-
comes.52 Most previous publications have reported
that women with AD have longer survival than
men.15,22,23,53,54 Increased risk for institutionalization
for women may have to do with cultural issues and
traditional sex roles (such as reluctance or inability
of husbands to provide home care for their wives).
Not surprisingly and similar to other reports,15,22,53
we found that presence of comorbid diseases was
associated with worse outcomes in AD.
The results of the adjusted models suggest that
both motor signs and worse baseline cognitive and
functional status are predicting poor outcomes. To
the extent that worse cognitive and functional per-
formance indicate higher disease severity, it is not
surprising that associations with poor outcomes have
been demonstrated almost universally.7,15,20-22,53 The
fact that presence and rate of accumulation of motor
signs are significant in the adjusted models suggests
that motor signs represent a true predictive factor,
over and above disease severity measures. However,
we cannot completely exclude the possibility that
some aspects of disease progression may not be com-
pletely captured by the cognitive or functional mea-
sures we control for and could potentially be
uniquely manifested by the presence of motor signs.
To this extent, some of the associations between mo-
tor signs and outcome may reflect being further
along in the disease course.
This study has limitations. Patients with AD were
selected from tertiary care University hospitals and
specialized diagnostic and treatment centers and
thus represent a nonrandom sample of those affected
by AD in the population. In addition, the proportion
of nonwhites in our sample was small. Therefore our
results might not be generalizable to population-
based AD and all ethnicities. Although we used sur-
vival analyses, which take advantage of variable
follow-up times, a longer average duration of
follow-up may have provided a more complete con-
clusion. This could have been achieved with enroll-
ment of patients at even earlier stages of their
disease or even before symptom onset; however, it is
not clear that this would change the results since
motor signs are usually absent early in the disease.
We did not administer the full UPDRS scale, which
may have restricted the full range of impairment, in
particular for appendicular bradykinesia. However,
the items were selected on the basis of earlier char-
acterization of motor signs in AD. Also, assessment
of motor signs is often difficult and rater related. It
is also very difficult to distinguish subtleties of vari-
ous aspects of the motor examination (such as differ-
ent types of tone, velocity of movements, and gait
abnormalities). However, we did not rely on clinical
assessments but instead used a scale that has been
shown to have good reliability properties and yields
high rates of agreements across interviewers. Also,
the raters were instructed to rate the parkinsonian
aspect of motor abnormalities in patients with AD.
Still, it is possible that we had not been able to
accurately distinguish between the various qualita-
tive types of motor disturbances.
In general, confidence in our findings is strength-
ened by several factors. This is one of the largest
studies of its kind examining in detail the issue of
motor signs in AD, supplying enough power for de-
tection and more precise calculation of effects of in-
terest and ability to control for potential
confounders. A major contribution of the present
analyses lies in the careful diagnosis and clinical
follow-up that patients received. Clinical diagnosis
took place in University hospitals with specific ex-
pertise in dementia and was based on uniform appli-
cation of widely accepted criteria via consensus
diagnostic conference procedures. The clinical diag-
nosis of AD has been confirmed in a high proportion
(96%) of those who have come to postmortem evalua-
tion.4 The patients were followed prospectively,
which eliminates the potential biases inherent in de-
riving information from retrospective chart reviews.
Evaluations were performed semiannually, which
provides multiple assessments of motor signs and
therefore permits more accurate coefficient calcula-
tions. They were also considered in a time-dependent
fashion. Our study had very high rate of follow-up
participation with very few missing data. Clinical
signs of interest were ascertained and coded in a
standardized fashion at each visit. Most previous re-
ports studied more impaired patients with AD, cap-
turing the disease at its more advanced stages.
Baseline CMMS score for this cohort was 38.2, corre-
sponding to a MMSE of 21; therefore, patients with
AD were included from early stages so that the co-
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hort describes the full range of progression over
time. Patients were drawn from multiple locations,
which increases generalizability of the findings. Re-
ported associations between motor signs and out-
comes in many previous studies have been
confounded by not taking into account use of medica-
tions that may produce motor signs. We excluded
patient-evaluations with medications that could pro-
duce parkinsonism, which provides higher confi-
dence that the occurrence of motor signs in the
present study is spontaneous, and related only to the
underlying disease processes.
Prognosis is a standard part of a medical evalua-
tion and knowledge of prognostic indicators is impor-
tant information for practitioners, patients, and
families. These data provide a basis for expanding
our understanding of predictors in the course of AD.
We add to the previous literature by confirming pre-
vious reports that motor signs are associated with
poor outcomes and by reporting associations between
individual domains of motor signs and particular
outcomes. The underlying pathophysiologic sub-
strate of the associations between motor signs and
clinical outcomes remains to be explored.
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NeuroImages
Man-in-the-barrel syndrome caused by a
pontine lesion
M. Paulin, MD; J. de Seze, MD; P. Wyremblewski, MD;
H. Zéphir, MD; D. Leys, MD; and P. Vermersch, MD,
Lille, France
A 78-year-old hypertensive woman suddenly developed an
acute brachial diplegia corresponding to man-in-the-barrel (MIB)
syndrome. Clinical examination results were otherwise normal,
including reflexes. Spinal cord MRI was normal. Brain MRI re-
vealed a bilateral hypersignal in the pons without frontal lesion
(figure). Three months later the patient had completely recovered.
MIB syndrome is an unusual feature that has been reported in
bilateral watershed infarcts, cervical spinal lesions, and motor
neuron disease.1-3 The most likely cause in our case was the pon-
tine lesion, presumably of ischemic origin. This is the first case of
MIB reported in association with a pontine lesion. It suggests that
pyramidal fibers supplying upper-limb function may be located
medially at the pontine level.
Copyright © 2005 by AAN Enterprises, Inc.
1. Crisostomo EA, Suslavich FJ. Man-in-the-barrel syndrome associated
with closed head injury. J Neuroimaging 1994;4:116–117.
2. Berg D, Mullges W, Koltzenburg M, Bendszus M, Reiners K. Man-in-the-
barrel syndrome caused by cervical spinal cord infarction. Acta Neurol
Scand 1998;97:417–419.
3. Katz JS, Wolfe GI, Andersson PB, et al. Brachial amyotrophic diplegia: a
slowly progressive motor neuron disorder. Neurology 1999;53:1071–
1076.
Address correspondence and reprint requests to Dr. J. de Seze, Department
of Neurology, Hôpital R. Salengro, CHRU de Lille, 59037 Lille Cedex,
France; e-mail: j-deseze@chru-lille.fr
Figure. Brain MRI, T2-weighted im-
ages, sagittal (A) and axial (B) plane,
showing a bilateral hyperintense signal
in the pons.
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